ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE American: BTX), een biotechnologisch bedrijf dat focust op de ontwikkeling en vermarkting van producten voor de behandeling van degeneratieve ziekten, heeft vandaag bekendgemaakt dat Adi Mohanty, co-CEO, en Russell Skibsted, financieel bestuurder, deelnemen aan de Jefferies London Healthcare Conference 2017. Die vindt op 15 en 16 november plaats in Londen, in het Verenigd Koninkrijk.

De Jefferies London Healthcare Conference is de grootste conferentie voor de gezondheidszorg in Europa. Naar verwachting nemen 350 bedrijven uit alle delen van de wereld deel aan het evenement. Het tweedaagse evenement bestaat uit twee gelijktijdige ‘tracks’ met bedrijfspresentaties, thematische panelgesprekken en één-op-één-gesprekken en en kleinschalige bijeenkomsten.

BioTime to Participate in the Jefferies 2017 London Healthcare Conference

ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will participate in the Jefferies 2017 London Healthcare Conference on November 15^th and 16^th, in London, United Kingdom.

The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. There is expected to be over 350 participating companies from around the world. The two-day event will include concurrent tracks of company presentations, thematic panel discussions and 1×1/small-group meetings.

One-on-one meetings with Mr. Mohanty and/or Mr. Skibsted can be arranged by scheduling through the Jefferies 1×1 desk or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or dnakasone@biotime.com.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and a private company, AgeX Therapeutics.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006995/en/

Contacts

Investor Contact:
BioTime
David Nakasone, 510-871-4188
Dnakasone@biotime.com
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com